Amicus Therapeutics' Q2 revenue up more than expected on Galafold demand
Overview
Amicus Q2 2025 revenue of $154.7 mln beats analyst expectations
Galafold Q2 revenue rises 12% at CER, driven by patient demand
Co reiterates 2025 guidance for GAAP profitability in H2 2025
Outlook
Amicus expects 2025 revenue growth of 15% to 22%
Company anticipates GAAP profitability in H2 2025
Galafold revenue growth projected at 10% to 15% in 2025
Pombiliti + Opfolda revenue growth expected at 50% to 65% in 2025
Result Drivers
GALAFOLD DEMAND - Driven by patient demand and strong compliance, Galafold revenue rose 12% at CER
POMBILITI + OPFOLDA LAUNCHES - High demand and new launches in five countries fueled 58% revenue growth at CER
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $154.70 mln | $147.10 mln (11 Analysts) |
Q2 EPS |
| -$0.08 |
|
Q2 Net Income |
| -$24.40 mln |
|
Q2 Adjusted Operating Expenses |
| $30 mln |
|
Q2 Operating Expenses |
| $30 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Amicus Therapeutics Inc is $15.00, about 59.1% above its July 30 closing price of $6.13
The stock recently traded at 76 times the next 12-month earnings vs. a P/E of 79 three months ago
Press Release: ID:nGNX6DRVY
